HeartBeam Presents Positive Results on its Artificial Intelligence Capabilities for Detecting Arrhythmias
09 Aprile 2024 - 2:31PM
Business Wire
New Data Presented at the European Heart Rhythm
Association Conference Marks First Scientific Presentation on
HeartBeam AI, the Company’s Deep Learning Technology
Data Shows HeartBeam AI Combined with VCG
Greatly Improves Detection of Atrial Flutter over Single-Lead ECGs
Found in Leading Smartwatches and Other Wearables
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology
company focused on transforming cardiac care through the power of
personalized insights, today announced new data demonstrating that
applying the company’s artificial intelligence (AI) algorithms to
vectorcardiography (VCG) showed considerably improved performance
in the detection of atrial flutter over single-lead
electrocardiograms (ECGs) and similar performance to 12-lead ECGs,
the standard for diagnosing atrial flutter. This marks the first
scientific presentation on the company’s deep learning algorithm,
HeartBeam AI. The data was presented by Vivek Reddy, MD, Director
of Cardiac Arrhythmia Services at The Mount Sinai Hospital, during
the European Heart Rhythm Association (EHRA) conference in Berlin,
Germany.
In the study, HeartBeam AI with VCG demonstrated a 28%
improvement over single-lead ECG in the detection of atrial flutter
cases (sensitivity of 91.0% for VCG vs. 71.2% for single-lead ECG)
without sacrificing the ability to identify those individuals
without atrial flutter (specificity of 98.7% for VCG vs. 96.9% for
single-lead ECG). Additional details about the study can be found
here.
Smartwatches have become increasingly popular for detecting and
monitoring abnormalities in the timing or pattern of heartbeats but
only offer a single-lead ECG, which greatly limits their ability to
detect a broad range of cardiac irregularities. Atrial flutter is a
common irregularity, or arrhythmia, that typically requires a
healthcare professional to administer a 12-lead ECG in a medical
setting which is not always practical or even possible at the time
of a cardiac event.
HeartBeam’s core vectorelectrocardiography (3D VECG) technology
captures the heart’s signals in three projections (X, Y, Z),
similar to VCG, and synthesizes a 12-lead ECG. The technology is
designed to be used in HeartBeam’s small, portable,
patient-friendly devices that allow for remote cardiac monitoring.
The Company’s first planned application of the 3D VECG platform
technology is the HeartBeam AIMIGo™, a credit card-sized device for
patient use at home or anywhere, which is currently under review
with FDA.
“The study presented at the EHRA conference shows that HeartBeam
AI combined with VCG delivers equivalent performance to a 12-lead
ECG and greatly improves detection of atrial flutter over a
single-lead ECG, underscoring the limitations of current wearable
technologies. This presents an opportunity for a VCG-based
algorithm that offers arrhythmia detection capabilities beyond what
is available today and to fill gaps in healthcare inequality when
obtaining a 12-lead ECG is challenging,” said Dr. Reddy.
The HeartBeam technology gathers far more data than a
single-lead ECG. By leveraging AI to analyze these data-rich
signals, HeartBeam believes it will be able to improve diagnostic
accuracy and the technology has the potential to extract unique
information that could go beyond today’s 12-lead ECGs as data of
great diagnostic value is gathered from the same patients using the
device over time. HeartBeam believes this presents a unique
opportunity to create a comprehensive repository of data that could
unlock personalized AI-driven insights to improve cardiac care.
“The intent of our AI program is to leverage our novel VECG
platform to unlock detection and prediction capabilities currently
limited to healthcare facilities and make them readily accessible
and available to the patient, and this new data is a clear example
of what we can accomplish,” said Branislav Vajdic, PhD, CEO and
Founder of HeartBeam. “As we continue to expand our artificial
intelligence capabilities, we look forward to demonstrating how the
combination of our data rich 3D VECG platform with HeartBeam AI has
the potential to transform how cardiac health is managed in the
future.”
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company
that is dedicated to transforming cardiac care through the power of
personalized insights. The company’s proprietary
vectorelectrocardiography (VECG) technology collects 3D signals of
the heart’s electrical activity and converts them into a 12-lead
ECG. This platform technology is designed to be used on portable,
patient-friendly devices such as a credit-card sized monitor, watch
or patch. Physicians will be able to identify cardiac health trends
and acute conditions and direct patients to the appropriate care –
all outside of a medical facility, thus redefining how cardiac
health is managed in the future. For additional information, visit
HeartBeam.com.
Forward-Looking Statements
All statements in this release that are not based on historical
fact are "forward-looking statements." While management has based
any forward-looking statements included in this release on its
current expectations, the information on which such expectations
were based may change. Forward-looking statements involve inherent
risks and uncertainties which could cause actual results to differ
materially from those in the forward-looking statements, as a
result of various factors including those risks and uncertainties
described in the Risk Factors and in Management’s Discussion and
Analysis of Financial Condition and Results of Operations sections
of our Forms 10-K, 10-Q and other reports filed with the SEC and
available at www.sec.gov. We urge you to consider those risks and
uncertainties in evaluating our forward-looking statements. We
caution readers not to place undue reliance upon any such
forward-looking statements, which speak only as of the date made.
Except as otherwise required by the federal securities laws, we
disclaim any obligation or undertaking to publicly release any
updates or revisions to any forward-looking statement contained
herein (or elsewhere) to reflect any change in our expectations
with regard thereto or any change in events, conditions or
circumstances on which any such statement is based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240409880945/en/
Investor Relations Contact: Chris Tyson Executive Vice
President MZ North America Direct: 949-491-8235 BEAT@mzgroup.us
www.mzgroup.us
Media Contact:media@heartbeam.com
Grafico Azioni HeartBeam (NASDAQ:BEAT)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni HeartBeam (NASDAQ:BEAT)
Storico
Da Dic 2023 a Dic 2024